Literature DB >> 9660997

In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa.

H Ishida1, Y Ishida, Y Kurosaka, T Otani, K Sato, H Kobayashi.   

Abstract

Interactions between biofilm cells of Pseudomonas aeruginosa and levofloxacin were studied. P. aeruginosa incubated for 6 days with Teflon sheets formed a biofilm on its surface. Against the biofilm bacteria, levofloxacin at an MIC determined by the standard method for the strain was highly bactericidal whereas gentamicin, ceftazidime, and ciprofloxacin showed no significant killing activity. Levofloxacin, ciprofloxacin, and gentamicin, but not ceftazidime, exhibited killing activity against nongrowing cells of the strain incubated in phosphate buffer. In addition, levofloxacin, ciprofloxacin, and ceftazidime, but not gentamicin, showed the ability to penetrate an agar containing alginate. These findings may explain the efficacy of levofloxacin and the ineffectiveness of gentamicin and ceftazidime against biofilm bacteria; however, the cause of the ineffectiveness of ciprofloxacin still remains to be determined. In experimental pneumonia in guinea pigs, in which the biofilm mode of growth of the strain was observed in the lung, only levofloxacin exhibited substantial therapeutic efficacy. These findings suggest the significant role of levofloxacin in therapy of biofilm bacterium-associated infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660997      PMCID: PMC105659     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  An in vivo model to study the pathobiology of infectious biofilms on biomaterial surfaces.

Authors:  A Buret; K H Ward; M E Olson; J W Costerton
Journal:  J Biomed Mater Res       Date:  1991-07

2.  Inactivation of biofilm bacteria.

Authors:  M W LeChevallier; C D Cawthon; R G Lee
Journal:  Appl Environ Microbiol       Date:  1988-10       Impact factor: 4.792

3.  Biofilm accumulation model that predicts antibiotic resistance of Pseudomonas aeruginosa biofilms.

Authors:  P S Stewart
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

4.  Bactericidal activities of ofloxacin and its optically active isomer (DR-3355) on non-growing cells of Escherichia coli and Pseudomonas aeruginosa.

Authors:  M Tanaka; M Otsuki; T Nishino
Journal:  Chemotherapy       Date:  1992       Impact factor: 2.544

5.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

6.  Effects of ciprofloxacin, norfloxacin, and ofloxacin on in vitro adhesion and survival of Pseudomonas aeruginosa AK1 on urinary catheters.

Authors:  G Reid; S Sharma; K Advikolanu; C Tieszer; R A Martin; A W Bruce
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Effects of ciprofloxacin and protamine sulfate combinations against catheter-associated Pseudomonas aeruginosa biofilms.

Authors:  F Soboh; A E Khoury; A C Zamboni; D Davidson; M W Mittelman
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

8.  [Experimental pneumonia with Pseudomonas aeruginosa in immunosuppressed guinea pigs as a model for biofilm-associated infection].

Authors:  Y Ishida
Journal:  Kansenshogaku Zasshi       Date:  1995-05

9.  Bacterial biofilm in chronic airway infection.

Authors:  N Ohgaki
Journal:  Kansenshogaku Zasshi       Date:  1994-01

10.  Modulation of biofilms of Pseudomonas aeruginosa by quinolones.

Authors:  M Yassien; N Khardori; A Ahmedy; M Toama
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more
  32 in total

Review 1.  Riddle of biofilm resistance.

Authors:  K Lewis
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Microbial biofilms: from ecology to molecular genetics.

Authors:  M E Davey; G A O'toole
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

Review 3.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli.

Authors:  Trudy H Grossman; William O'Brien; Kathryn O Kerstein; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

Review 5.  Collective antibiotic tolerance: mechanisms, dynamics and intervention.

Authors:  Hannah R Meredith; Jaydeep K Srimani; Anna J Lee; Allison J Lopatkin; Lingchong You
Journal:  Nat Chem Biol       Date:  2015-02-17       Impact factor: 15.040

Review 6.  Recalcitrant Staphylococcus aureus Infections: Obstacles and Solutions.

Authors:  Sarah E Rowe; Jenna E Beam; Brian P Conlon
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

7.  Subinhibitory Concentrations of Mupirocin Stimulate Staphylococcus aureus Biofilm Formation by Upregulating cidA.

Authors:  Ye Jin; Yinjuan Guo; Qing Zhan; Yongpeng Shang; Di Qu; Fangyou Yu
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

8.  Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials.

Authors:  A L Spoering; K Lewis
Journal:  J Bacteriol       Date:  2001-12       Impact factor: 3.490

9.  Extracellular arginine aminopeptidase from Streptococcus gordonii FSS2.

Authors:  J M Goldstein; D Nelson; T Kordula; J A Mayo; J Travis
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

10.  Growing Burkholderia pseudomallei in biofilm stimulating conditions significantly induces antimicrobial resistance.

Authors:  Chakrit Sawasdidoln; Suwimol Taweechaisupapong; Rasana W Sermswan; Unchalee Tattawasart; Sumalee Tungpradabkul; Surasakdi Wongratanacheewin
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.